98 related articles for article (PubMed ID: 20518075)
21. Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells.
Wang W; Chong WP; Li C; Chen Z; Wu S; Zhou H; Wan Y; Chen W; Gery I; Liu Y; Caspi RR; Chen J
Cell Rep; 2019 Jul; 28(2):486-497.e4. PubMed ID: 31291583
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
Sharma SM; Damato E; Hinchcliffe AE; Andrews CD; Myint K; Lee R; Dick AD
Br J Ophthalmol; 2021 Sep; 105(9):1256-1262. PubMed ID: 30862619
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological treatment strategies and surgical options for uveitis].
Garweg JG
Ophthalmologe; 2019 Oct; 116(10):942-950. PubMed ID: 30796601
[TBL] [Abstract][Full Text] [Related]
24. Uveitis: contrasting the approaches in Japan and the United States.
Rosenbaum JT
Jpn J Ophthalmol; 2019 Jan; 63(1):1-6. PubMed ID: 30460514
[TBL] [Abstract][Full Text] [Related]
25. Interferon-α2a treatment for refractory Behçet's disease.
Lai YJ; Chan WC
Taiwan J Ophthalmol; 2018; 8(3):168-172. PubMed ID: 30294531
[TBL] [Abstract][Full Text] [Related]
26. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients.
Lee JH; Lee CS; Lee SC
BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220
[TBL] [Abstract][Full Text] [Related]
27. A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.
Sharma SM; Fu DJ; Xue K
Ophthalmol Ther; 2018 Jun; 7(1):1-17. PubMed ID: 29189960
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review.
Gómez-Gómez A; Loza E; Rosario MP; Espinosa G; Morales JMGR; Herreras JM; Muñoz-Fernández S; Cordero-Coma M
Medicine (Baltimore); 2017 Oct; 96(42):e8045. PubMed ID: 29049193
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.
Hornbeak DM; Thorne JE
Taiwan J Ophthalmol; 2015; 5(4):156-163. PubMed ID: 29018691
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression for the Uveitides.
Jabs DA
Ophthalmology; 2018 Feb; 125(2):193-202. PubMed ID: 28942074
[TBL] [Abstract][Full Text] [Related]
31. [Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].
Kötter I; Stübiger N; Deuter C
Z Rheumatol; 2017 Oct; 76(8):673-681. PubMed ID: 28861674
[TBL] [Abstract][Full Text] [Related]
32. The Role of Th17 Cells in the Pathogenesis of Behcet's Disease.
Nanke Y; Yago T; Kotake S
J Clin Med; 2017 Jul; 6(7):. PubMed ID: 28753995
[TBL] [Abstract][Full Text] [Related]
33. An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally TW; Damato EM; Murray PI; Denniston AK; Barry RJ
Orphanet J Rare Dis; 2017 Jul; 12(1):130. PubMed ID: 28716038
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
[TBL] [Abstract][Full Text] [Related]
35. A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease.
Figus M; Posarelli C; Albert TG; Talarico R; Nardi M
Biomed Res Int; 2015; 2015():120519. PubMed ID: 26558256
[TBL] [Abstract][Full Text] [Related]
36. Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease.
Lopalco G; Lucherini OM; Vitale A; Talarico R; Lopalco A; Galeazzi M; Lapadula G; Cantarini L; Iannone F
Medicine (Baltimore); 2015 Oct; 94(42):e1858. PubMed ID: 26496336
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials in noninfectious uveitis.
Kim JS; Knickelbein JE; Nussenblatt RB; Sen HN
Int Ophthalmol Clin; 2015; 55(3):79-110. PubMed ID: 26035763
[TBL] [Abstract][Full Text] [Related]
38. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
[TBL] [Abstract][Full Text] [Related]
39. Immunopathogenesis of ocular Behçet's disease.
Park UC; Kim TW; Yu HG
J Immunol Res; 2014; 2014():653539. PubMed ID: 25061613
[TBL] [Abstract][Full Text] [Related]
40. Decreased interleukin 27 expression is associated with active uveitis in Behçet's disease.
Wang C; Tian Y; Ye Z; Kijlstra A; Zhou Y; Yang P
Arthritis Res Ther; 2014 May; 16(3):R117. PubMed ID: 24887071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
